Introduction/Overview
Cough is one of the most common symptoms of respiratory diseases, which is not only an important defensive reflex of the body, but also a clinical manifestation of various acute and chronic diseases. Although modern medicine has developed various cough suppressants, central cough suppressants (such as codeine) have addictive and respiratory inhibitory side effects, while peripheral cough suppressants have relatively limited options and varying therapeutic effects. Therefore, searching for efficient and low toxicity natural cough suppressant active ingredients from traditional medicinal plants has always been an important direction for drug development. Aster（Aster tataricus L. F.) As a traditional Chinese medicine, its roots and rhizomes (Aster) have the effects of moistening lung qi, resolving phlegm and stopping cough, and have a long history of clinical application. Shionone (CAS number: 10376-48-4), as a characteristic triterpenoid compound isolated from Aster, has attracted widespread attention from natural product pharmacology researchers in recent years due to its unique chemical structure and significant pharmacological activities such as cough suppression and anti-inflammatory effects. This article aims to systematically review the chemical properties, plant sources, pharmacological activities, mechanisms of action, pharmacological evaluation, and clinical application prospects of asterone, in order to provide comprehensive scientific references for the in-depth research and development of this natural product.
Chemical structure and physicochemical properties
Asterone is a pentacyclic triterpenoid compound with the molecular formula C30H50O and a molecular weight of 426.7290. Its most prominent structural feature lies in its unique six membered four ring skeleton (A/B/C/D rings) and an additional five membered E ring, forming a highly rigid five ring system. Specifically, its structure is a 3-oxo-4-monomethyl-lanostane triterpenoid, with a carbonyl (ketone) group at the C-3 position and an alpha methyl group at the C-4 position. This 3-oxo structure is one of its important pharmacophores, closely related to its biological activity. Its skeleton is significantly different from the common oleanane or ursolic triterpenoids, endowing it with special physicochemical properties and biological activity.
From the analysis of parameters related to drug properties, asterone exhibits typical lipophilic characteristics. Its calculated lipid water partition coefficient (LogP) is as high as 8.8865, indicating its extremely strong lipid solubility. Consistent with this, its water solubility is extremely low, about 0.0002 mg/mL, which poses a challenge for its formulation development. Its topological polar surface area (TPSA) is only 17.0700 Å ², further confirming its low molecular polarity. These physicochemical properties determine the distribution characteristics of fisetin in organisms: its blood-brain barrier permeability is predicted to be "high", suggesting that it may easily enter the central nervous system, which may be a favorable factor for its cough suppressant activity targeting central targets. In terms of early safety indicators, existing prediction models show no significant risk of hERG potassium channel inhibition (hERG inhibition: no), and the Ames test prediction value is 0.0, indicating a low risk of mutagenicity and providing preliminary positive signals for its safety evaluation.
Plant sources and extraction methods
Asterone is mainly derived from the Asteraceae plant Aster（Aster tataricus L. F.) Dry roots and rhizomes. Aster is mainly distributed in East Asian regions such as China, Japan, and South Korea. It has a long history of medicinal use in China and has been included in multiple editions of the Chinese Pharmacopoeia. As a medicinal herb, Aster is commonly used to treat symptoms such as cough, phlegm, and asthma.
The extraction and isolation of asterone from the medicinal herb Aster usually follow the conventional process of natural product chemistry. Firstly, organic solvents are used for extraction. Due to the strong lipid solubility of puerarin, strong polar solvents such as chloroform, ethyl acetate, acetone, or high concentration ethanol are often used for reflux extraction or ultrasound assisted extraction. After concentration, the crude extract is preliminarily separated by utilizing the polarity difference between ketone and other coexisting components (such as flavonoids, saponins, other triterpenes, etc.) using silica gel column chromatography and gradient elution systems such as petroleum ether ethyl acetate or chloroform methanol. Asterone is usually enriched in moderately polar elution sites. Further purification can be achieved by repeated silica gel column chromatography, preparative thin layer chromatography (PTLC), or high-performance liquid chromatography (HPLC, often using a reverse phase C18 column with methanol water or acetonitrile water as the mobile phase). Modern separation techniques such as high-speed countercurrent chromatography (HSCCC) have also been applied to the efficient preparation and separation of ketone due to their advantages of not requiring a solid phase carrier and high recovery rate. The optimization goal of the extraction and separation process is to improve the yield and purity of puerarin, in order to meet the needs of subsequent pharmacological research and formulation development.
Pharmacological activity research
A large number of preclinical pharmacological studies have confirmed that fisetin has multiple biological activities, among which its cough suppressant and anti-inflammatory effects are the most prominent.
-
Cough suppressant activity This is the core pharmacological effect of asterone. In classic animal cough models induced by chemical stimuli (such as citric acid and ammonia water) and mechanical stimuli, oral or intraperitoneal administration of fisetin can significantly prolong cough latency and reduce cough frequency, and its cough suppression intensity shows a dose-dependent relationship within a certain dose range. Research has shown that its cough suppressant effect is comparable or slightly weaker than certain positive control drugs (such as codeine), but its advantage lies in its mechanism of action, which may be more biased towards multi-target regulation of the peripheral and/or central nervous system rather than simple central anesthesia, resulting in potentially fewer side effects.
-
anti-inflammatory activity Inflammation is an important pathological basis for the occurrence and persistence of cough symptoms in many respiratory diseases, such as bronchitis and asthma. Asterone has shown good anti-inflammatory effects in various acute and chronic inflammation models. For example, in acute inflammation models such as xylene induced mouse ear swelling and carrageenan induced rat paw swelling, fisetin can significantly inhibit tissue edema. In the lipopolysaccharide (LPS) - stimulated macrophage model (such as RAW264.7), fisetin can dose dependently inhibit the production of key pro-inflammatory mediators such as nitric oxide (NO), prostaglandin E2 (PGE2), tumor necrosis factor - α (TNF - α), and interleukin-6 (IL-6). Its anti-inflammatory effect and cough suppressing activity complement each other, jointly alleviating airway hyperresponsiveness and cough reflex sensitivity.
-
Other activities In addition, studies have reported potential activities such as antioxidant, anti-tumor (such as inhibiting the proliferation of certain cancer cells), and neuroprotective effects of asterone. These activities have expanded the application potential of puerarin, but its correlation and specific mechanism with the main cough suppressing effect still need to be further explored.
Mechanism of action and molecular targets
The cough suppressant mechanism of astragalenone is complex, involving the regulation of multiple key molecular targets in the cough reflex pathway, reflecting the characteristics of multi-target intervention. Current research suggests that its targets mainly focus on transient receptor potential (TRP) channels, neuropeptides and their receptors, ion channels, etc.
-
TRP channel antagonistic effect Transient receptor potential vanillic acid subtype 1 (TRPV1) and transient receptor potential anchor protein subtype 1 (TRPA1) are key cough receptors expressed in the sensory nerve endings of the airway, which can be activated by various chemical and physical stimuli, triggering cough reflex. Research has shown that fisetin may be an antagonist of TRPV1 and TRPA1 channels, reducing the excitability of sensory nerves by inhibiting the opening of these channels, thereby reducing the transmission of cough impulses to the central nervous system. This is one of the core mechanisms by which it exerts peripheral cough suppressing effects.
-
Regulation of neuropeptide system The cough reflex involves the release of multiple neuropeptides. Calcitonin gene-related peptide (encoded by the CalcA gene) and substance P (encoded by the TAC1 gene) are important cough promoting neuropeptides. Asterone may weaken its stimulating effects on the airway and cough center by inhibiting the synthesis or release of these neuropeptides. In addition, gastrin releasing peptide receptor (GRPR) and neuromodulatory peptide U receptor 1 (NMUR1) play important roles in central cough regulation, and fisetin may regulate the sensitivity of the cough center by affecting these receptor pathways.
-
Opioid receptor system The μ - opioid receptor (OPRM1) is a classic target of central cough suppressants such as codeine. Some studies speculate that fisetin or its metabolites may have a certain regulatory effect on OPRM1, which may be a potential pathway for its partial central cough suppression effect. However, whether it is an excitatory, partially excitatory, or regulatory effect still needs to be clarified.
-
Voltage-Gated Sodium Channel The Nav1.7 sodium channel encoded by SCN9A is crucial in pain and sensory signal transduction, and may also be involved in signal transduction in pathological cough. Asterone may affect the generation and conduction of action potentials in sensory nerves by regulating the activity of such ion channels.
In summary, asterone may exert its cough suppressing effect through a "multi-target, multi pathway" approach: in the periphery, it mainly antagonizes TRPV1/TRPA1, inhibits the activation of sensory nerve endings and the release of neuropeptides; In the central nervous system, the excitability of the cough center may be regulated by affecting receptors such as GRPR, NMUR1, OPRM1, etc. Its anti-inflammatory effect is achieved by inhibiting signaling pathways such as NF - κ B and MAPK, reducing the production of pro-inflammatory cytokines and mediators, fundamentally alleviating airway inflammation, and reducing the sensitivity of cough reflex. This synergistic effect gives it a unique advantage in treating inflammation related cough.
Evaluation of drug properties and pharmacokinetics
Despite exhibiting good pharmacological activity, there are still some challenges and issues that require further research in terms of drug liking.
-
Absorption, distribution, metabolism, excretion (ADME)：
- absorb The extremely high lipophilicity (high LogP) is beneficial for its transmembrane passive diffusion, indicating that it may have good absorption in the small intestine after oral administration. However, its extremely low water solubility may lead to the dissolution rate becoming the rate limiting step for oral absorption, and its bioavailability may not be ideal.
- distribution High lipid solubility and low TPSA indicate a wide tissue distribution and easy penetration through biofilms. The predicted high blood-brain barrier permeability is consistent with its potential central action targets, which may contribute to the central cough suppression effect, but attention should also be paid to the risk of central side effects.
- Metabolism As a triterpenoid compound, asterone is likely to be mainly metabolized by the liver cytochrome P450 (CYP450) enzyme system in vivo. Its 3-keto group and multiple methyl groups may be metabolic sites. Clarifying its main metabolites, metabolic enzyme subtypes, and whether there are metabolic drug interactions is crucial for subsequent development.
- excretion Prototype drugs or metabolites may be mainly excreted through bile and feces, with some excreted through the kidneys.
-
Challenges and optimization strategies for drug development：
- Poor water solubility This is the biggest challenge faced by the development of asterone as an oral formulation. The solution strategy includes: ① Formulation technology Adopting formulation methods such as solid dispersion, cyclodextrin inclusion, nanocrystals, liposomes, etc. to improve its dissolution and bioavailability. ② Structural modification By using a semi synthetic method, hydrophilic groups (such as hydroxyl, carboxyl, glycosides, etc.) are introduced while retaining the pharmacophore to prepare derivatives or prodrugs with better water solubility.
- Insufficient pharmacokinetic research At present, there is still a lack of public reports on the pharmacokinetics of the asterone system, such as absolute bioavailability, half-life, and specific data on tissue distribution. It is urgent to conduct in-depth in vivo pharmacokinetic studies to provide a basis for dosage form design and administration regimens.
- safety evaluation Although there is no preliminary prediction of hERG inhibition and mutagenic risk, a comprehensive preclinical safety evaluation is still needed, including acute toxicity, chronic toxicity, reproductive toxicity, etc., to assess its therapeutic window.
Clinical application prospects and prospects
As a natural compound with clear cough suppressant and anti-inflammatory activity, asterone has broad clinical application prospects, but solid research work is still needed to pave the way for its transformation.
-
Potential application directions：
- Development of new cough suppressants In response to the current shortcomings in the cough suppressant market, such as the side effects of central cough suppressants and the limited efficacy of peripheral cough suppressants, the multi-target and combined peripheral and central mechanisms of action of asteronone make it a promising new, safer and more effective cough suppressant, especially suitable for inflammation related coughs such as post cold cough, chronic bronchitis, cough variant asthma, etc.
- Quality markers of traditional Chinese medicine Aster: Asterone can be used as one of the key quality markers of Aster and its related preparations (such as cough relieving and expectorant traditional Chinese patent medicines and simple preparations) to control the internal quality of the medicinal materials and products and ensure the stability and controllability of the curative effect.
- combination therapy Asterone can be used in combination with cough suppressants, expectorants, and bronchodilators with other mechanisms of action, which may produce synergistic effects and provide new candidate ingredients for the development of compound formulations.
-
Future research prospects：
- In depth mechanism research Using techniques such as gene knockout animals, selective antagonists, molecular docking, and point mutations, we aim to accurately verify the direct interaction sites and modes between fisetin and targets such as TRPV1, TRPA1, and GRPR, and elucidate its signaling network.
- Optimization of drug properties in the system Parallel promotion of formulation strategies (such as nano drug delivery systems) and medicinal chemistry strategies (structural modification) to improve their water solubility and pharmacokinetic properties, and screen for candidate molecules with better activity and drug properties.
- Expand activity spectrum research Based on its anti-inflammatory and antioxidant activities, explore its therapeutic potential in other fields such as chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and neuroinflammatory diseases.
- Conduct preclinical and clinical research After completing the pharmacological, pharmacokinetic, and safety evaluations of the system, push it into the clinical trial phase to verify its effectiveness and safety in humans.
Conclusion
Asterone is a unique and active pentacyclic triterpenoid compound discovered from the traditional cough suppressant herb Aster. A large number of preclinical studies have shown that it exerts significant cough and anti-inflammatory effects through a multi-target mechanism, mainly involving the regulation of TRPV1/TRPA1 channels, neuropeptide systems, and potential central receptors. Although its extremely low solubility and incomplete pharmacokinetic characteristics pose major challenges for its drug conversion, these challenges are expected to be overcome through the intervention of modern pharmaceutical chemistry and formulation techniques. In the future, in-depth mechanism research, drug efficacy optimization, and subsequent clinical translation exploration of asterone are expected to provide a new candidate drug for cough treatment, enrich the selection of cough suppressants, and also provide a successful example for innovative drug development based on traditional Chinese medicine knowledge. The research on asterone reflects the complete value chain of natural medicine research, from traditional experience to modern scientific interpretation, and then to innovative product development.
